Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.

This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn’s, Bronchopulmonary dysplasia, Epilepsy and Stroke.

Amsterdam, The Netherlands – 29 November 2018

The Cell Factory is expecting to complete the syndicate of investors to secure its Series A round as forecasted in their business planning for Q1 2019. The Cell Factory in collaboration with its academic partners have made a significant progress in pre-clinical development of its 1st generation and 2nd generation Extracellular Vesicles (EVs) drug candidates and is ready to start the first-in-man clinical trials in treatment of drug-resistant Crohn’s disease (CF-MEV-107). The Cell Factory is expecting the next EVs drug candidates to enter clinical tests in 2020 and 2021. The Company’s thinks that an IPO would take place as soon as the EVs drugs will prove safety and efficacy in clinic.

In addition to the EVs drug development, The Cell Factory is planning to offer the CDMO service for large-scale production of EVs using its proprietary technology and large-scale manufacturing capacity.

The Cell Factory business development strategy is focused on the commercialization of EVs drugs in the European market. Its geographic location at the Waterfront biopark, the heart for emerging Biotechs in the city of Niel, Belgium, creates a strong brand positioning.

The Cell Factory is also planning to enter the Chinese market and the US and Canada markets with its EVs drug candidates in the near future. CDMO division of The Cell Factory will be focused on large-scale manufacturing of the EVs for pharma industry considering their growing interest in EVs use as a drug delivery system. CDMO service will provide additional revenue for The Cell Factory and will be an attractive asset for the investors.

The Cell Factory’s business offer has attracted a significant interest of the investors during Sachs and BioEurope recent events. The Cell Factory is planning an investment tour in the US attending the Biotech Showcase in San Francisco in January 2019.

The Cell Factory is developing disruptive biologic drugs (Extracellular vesicles) as the alternative to the allogeneic cell therapies. Current drug portfolio is protected by international patents and includes four EVs immunotherapeutics targeting unmet medical needs in treatment of:
Crohn’s disease (CF-MEV-107) for the treatment of drug-resistant perianal fistulae and targeting local inflammation. The product has been successfully tested in animals and is ready for clinical translation into phase I to investigate the safety and preliminary efficacy in patients.

Bronchopulmonary dysplasia (CF-MEV -132) for treatment drug-resistant severe lung inflammation in premature birth children via intra-tracheal administration. The product has been successfully tested in animals and is ready for clinical translation in 2019/2020.

Epilepsy (CF-MEV-117) for treatment of drug-resistant brain inflammation and severe epileptic seizures in children. Brain delivery due to blood-brain-barrier penetration by EVs. The product is currently in pre-clinical development and clinical trials are expected in 2020/2021.

Stroke (CF-MEV-126) targeting acute inflammation of the central nervous system. Brain delivery due to blood-brain-barrier penetration by EVs. The product is currently in pre-clinical development and clinical trials are expected in 2020/2021.

About ESPERITE

ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.

About The Cell Factory

The Cell Factory, a subsidiary of the Esperite Group, is a biotechnology company focusing on the manufacturing process, development and clinical translation of therapeutic programs based on extracellular vesicles (EVs). The Cell Factory’s strategy is to become the leader in the production of these advanced extracellular vesicles (EVs) as biologic drugs for the treatment of: i.e., inflammatory diseases, graft versus host disease (GvHD) after solid organ and cell transplantations, arthritis, multiple sclerosis, cystic fibrosis, stroke, traumatic brain and spinal cord injury, newborn encephalopathy, and type 1 diabetes among others.

To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31_575_548_998 - ir@esperite.com or visit the websites at www.esperite.com, www.genoma.com and www.cryo-save.com.

***

This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).